Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat

Click here to get full coverage on Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential  Yahoo Finance

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative

Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News  Quiver Quantitative

Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics (DNTH): Reviewing Valuation Following Widening Losses in Latest Earnings Results - simplywall.st

Dianthus Therapeutics (DNTH): Reviewing Valuation Following Widening Losses in Latest Earnings Results  simplywall.st

Dianthus Therapeutics (DNTH): Reviewing Valuation Following Widening Losses in Latest Earnings Results - simplywall.st

Click here to get full coverage on Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2  Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan

Click here to get full coverage on 27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat

27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd  MarketBeat

27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on Insider Sale: EVP of $DNTH Sells 109,031 Shares - Quiver Quantitative

Insider Sale: EVP of $DNTH Sells 109,031 Shares  Quiver Quantitative

Insider Sale: EVP of $DNTH Sells 109,031 Shares - Quiver Quantitative

Click here to get full coverage on $150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan

$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development  Stock Titan

$150 Million Stock Offering: Biotech Dianthus Therapeutics Raises Funds for Autoimmune Drug Development - Stock Titan

Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why - MarketBeat

Click here to get full coverage on Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion - Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion  Yahoo Finance

Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion - Yahoo Finance

Click here to get full coverage on Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan

Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart  Stock Titan

Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan

Click here to get full coverage on Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat

Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC  MarketBeat

Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat

Click here to get full coverage on Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum - Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum  Yahoo Finance

Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise  Yahoo Finance

Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - Yahoo Finance

Click here to get full coverage on Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH  MarketBeat

Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Click here to get full coverage on Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares - MarketBeat

Click here to get full coverage on Do Weakening Revenues at Dianthus Therapeutics (DNTH) Challenge Its Clinical Development Ambitions? - Yahoo Finance

Do Weakening Revenues at Dianthus Therapeutics (DNTH) Challenge Its Clinical Development Ambitions?  Yahoo Finance

Do Weakening Revenues at Dianthus Therapeutics (DNTH) Challenge Its Clinical Development Ambitions? - Yahoo Finance

Click here to get full coverage on Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - Yahoo Finance

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target  Yahoo Finance

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - Yahoo Finance

Click here to get full coverage on Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH  MarketBeat

Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Click here to get full coverage on Behavioral Patterns of DNTH and Institutional Flows - news.stocktradersdaily.com

Behavioral Patterns of DNTH and Institutional Flows  news.stocktradersdaily.com

Behavioral Patterns of DNTH and Institutional Flows - news.stocktradersdaily.com

Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% - Here's What Happened - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% - Here's What Happened  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% - Here's What Happened - MarketBeat

Click here to get full coverage on IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25 - Stock Titan

IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25  Stock Titan

IND Cleared Sept 2025 — Dianthus In‑Licenses DNTH212 with $30M Upfront; Phase 1 to Start Q4'25 - Stock Titan

Click here to get full coverage on $288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan

$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs  Stock Titan

$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan

Click here to get full coverage on Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan

Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study  Stock Titan

Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan

Click here to get full coverage on How Investors Are Reacting To Dianthus Therapeutics (DNTH) Advancing Claseprubart After Positive Phase 2 Results - Sahm

How Investors Are Reacting To Dianthus Therapeutics (DNTH) Advancing Claseprubart After Positive Phase 2 Results  Sahm

How Investors Are Reacting To Dianthus Therapeutics (DNTH) Advancing Claseprubart After Positive Phase 2 Results - Sahm

Click here to get full coverage on Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Should You Buy? - MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Should You Buy?  MarketBeat

Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Should You Buy? - MarketBeat

Click here to get full coverage on We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth - simplywall.st

We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth  simplywall.st

We Think Dianthus Therapeutics (NASDAQ:DNTH) Can Afford To Drive Business Growth - simplywall.st

Click here to get full coverage on Aug Action: Can DNTH stock deliver 10 annual returns - Earnings Recap Summary & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ

Aug Action: Can DNTH stock deliver 10 annual returns - Earnings Recap Summary & Free Technical Pattern Based Buy Signals  BỘ NỘI VỤ

Aug Action: Can DNTH stock deliver 10 annual returns - Earnings Recap Summary & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ

Click here to get full coverage on Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH  MarketBeat

Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat

Click here to get full coverage on Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion - Stock Titan

Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion  Stock Titan

Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion - Stock Titan

Click here to get full coverage on Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares - Quiver Quantitative

Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares  Quiver Quantitative

Insider Sale: CFO & CBO of $DNTH Sells 20,000 Shares - Quiver Quantitative

Click here to get full coverage on Equities Analysts Offer Predictions for DNTH FY2025 Earnings - MarketBeat

Equities Analysts Offer Predictions for DNTH FY2025 Earnings  MarketBeat

Equities Analysts Offer Predictions for DNTH FY2025 Earnings - MarketBeat

Click here to get full coverage on New Analyst Forecast: $DNTH Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $DNTH Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $DNTH Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on How DNTH stock compares to growth peers - 2025 Dividend Review & Scalable Portfolio Growth Ideas - Newser

How DNTH stock compares to growth peers - 2025 Dividend Review & Scalable Portfolio Growth Ideas  Newser

How DNTH stock compares to growth peers - 2025 Dividend Review & Scalable Portfolio Growth Ideas - Newser

Click here to get full coverage on Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock - MarketBeat

Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock  MarketBeat

Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock - MarketBeat

Click here to get full coverage on New Analyst Forecast: $DNTH Given $40.0 Price Target - Quiver Quantitative

New Analyst Forecast: $DNTH Given $40.0 Price Target  Quiver Quantitative

New Analyst Forecast: $DNTH Given $40.0 Price Target - Quiver Quantitative

Click here to get full coverage on Notable Wednesday Option Activity: ISRG, DNTH, CNR - Nasdaq

Notable Wednesday Option Activity: ISRG, DNTH, CNR  Nasdaq

Notable Wednesday Option Activity: ISRG, DNTH, CNR - Nasdaq

Click here to get full coverage on Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment - Stock Titan

Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment  Stock Titan

Dianthus (NASDAQ: DNTH) advances CAPTIVATE interim to Q2 2026 on faster enrollment - Stock Titan

Click here to get full coverage on New Analyst Forecast: $DNTH Given $46.0 Price Target - Quiver Quantitative

New Analyst Forecast: $DNTH Given $46.0 Price Target  Quiver Quantitative

New Analyst Forecast: $DNTH Given $46.0 Price Target - Quiver Quantitative

Click here to get full coverage on Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - Investor's Business Daily

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again  Investor's Business Daily

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again - Investor's Business Daily

Click here to get full coverage on Dianthus Therapeutics (Nasdaq: DNTH) plans CEO fireside chats at four November conferences - Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) plans CEO fireside chats at four November conferences  Stock Titan

Dianthus Therapeutics (Nasdaq: DNTH) plans CEO fireside chats at four November conferences - Stock Titan

Click here to get full coverage on Dianthus therapeutics EVP Randhawa sells $7.3m in shares - Investing.com

Dianthus therapeutics EVP Randhawa sells $7.3m in shares  Investing.com

Dianthus therapeutics EVP Randhawa sells $7.3m in shares - Investing.com

Click here to get full coverage on Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative

Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis  Quiver Quantitative

Dianthus Therapeutics Announces Conference Call to Discuss Phase 2 MaGic Trial Results for Claseprubart in Generalized Myasthenia Gravis - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com

Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data  Investing.com

Dianthus Therapeutics stock soars after positive Phase 2 gMG trial data - Investing.com

Click here to get full coverage on Leads Biolabs joins a $1B development deal with Dianthus - BioWorld MedTech

Leads Biolabs joins a $1B development deal with Dianthus  BioWorld MedTech

Leads Biolabs joins a $1B development deal with Dianthus - BioWorld MedTech

Click here to get full coverage on Notable Friday Option Activity: GLW, DNTH, CROX - Nasdaq

Notable Friday Option Activity: GLW, DNTH, CROX  Nasdaq

Notable Friday Option Activity: GLW, DNTH, CROX - Nasdaq

Click here to get full coverage on Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal - Investing.com

Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal  Investing.com

Dianthus Therapeutics stock rating reiterated by TD Cowen after license deal - Investing.com

Click here to get full coverage on DNTH: HC Wainwright & Co. Raises Price Target to $47.00, Maintai - GuruFocus

DNTH: HC Wainwright & Co. Raises Price Target to $47.00, Maintai  GuruFocus

DNTH: HC Wainwright & Co. Raises Price Target to $47.00, Maintai - GuruFocus

Click here to get full coverage on Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal - Investing.com

Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal  Investing.com

Dianthus Therapeutics stock maintains Buy rating at Guggenheim after licensing deal - Investing.com

Click here to get full coverage on Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com

Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright  Investing.com

Dianthus Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com

Click here to get full coverage on Dianthus, Opendoor, and More Stocks See Action From Activist Investors - Barron's

Dianthus, Opendoor, and More Stocks See Action From Activist Investors  Barron's

Dianthus, Opendoor, and More Stocks See Action From Activist Investors - Barron's

Click here to get full coverage on Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating - Investor's Business Daily

Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating  Investor's Business Daily

Stocks Showing Market Leadership: Dianthus Therapeutics Earns 91 RS Rating - Investor's Business Daily

Click here to get full coverage on Dianthus Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Dianthus Therapeutics Reports Positive Phase 2 Trial Results  TipRanks

Dianthus Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Click here to get full coverage on A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha

A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH)  Seeking Alpha

A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics stock price target raised to $60 by Oppenheimer - Investing.com

Dianthus Therapeutics stock price target raised to $60 by Oppenheimer  Investing.com

Dianthus Therapeutics stock price target raised to $60 by Oppenheimer - Investing.com

Click here to get full coverage on Dianthus Therapeutics Signs License Agreement with Nanjing Leads - TipRanks

Dianthus Therapeutics Signs License Agreement with Nanjing Leads  TipRanks

Dianthus Therapeutics Signs License Agreement with Nanjing Leads - TipRanks

Click here to get full coverage on The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity  Benzinga

The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga

Click here to get full coverage on Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of Action | DNTH Stock News - Quiver Quantitative

Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of Action | DNTH Stock News  Quiver Quantitative

Dianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of Action | DNTH Stock News - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative

Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026  Quiver Quantitative

Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative

Click here to get full coverage on Dianthus Therapeutics, Inc. Updates Corporate Presentation - TradingView

Dianthus Therapeutics, Inc. Updates Corporate Presentation  TradingView

Dianthus Therapeutics, Inc. Updates Corporate Presentation - TradingView

Click here to get full coverage on Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha

Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead  Seeking Alpha

Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead - Seeking Alpha

Click here to get full coverage on Dianthus Therapeutics Insider Sold Shares Worth $7,379,887, According to a Recent SEC Filing - marketscreener.com

Dianthus Therapeutics Insider Sold Shares Worth $7,379,887, According to a Recent SEC Filing  marketscreener.com

Dianthus Therapeutics Insider Sold Shares Worth $7,379,887, According to a Recent SEC Filing - marketscreener.com

Click here to get full coverage on Guggenheim Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $92 - 富途牛牛

Guggenheim Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $92  富途牛牛

Guggenheim Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $92 - 富途牛牛

Click here to get full coverage on Dianthus Therapeutics stock hits 52-week high at 38.65 USD - Investing.com

Dianthus Therapeutics stock hits 52-week high at 38.65 USD  Investing.com

Dianthus Therapeutics stock hits 52-week high at 38.65 USD - Investing.com

Click here to get full coverage on Guggenheim Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $92 - 富途牛牛

Guggenheim Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $92  富途牛牛

DNTH

Price Chart

Key Statistics

Technicals

About DNTH

Latest News

Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance

Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers